AMG-510 is a potent KRAS G12C covalent inhibitor with potential antineoplastic activity. At the 2019 World Conference on Lung Cancer (WCLC), Amgen declared the efficacy of AMG 510 for treating non-small cell lung cancer (NSCLC) with KRAS G12 C-mutated solid tumors. Amgen also announced prospective directions for AMG510 through academic scholars and reports the few limitations on official drug release as evidence for potential investors to consider the value of AMG 510.
Products > Drug Discovery > Inhibitor | Products > Drug Discovery > Inhibitor | Cancer | K-Ras
感谢您来到爆牛贸易,请为我们留言或者使用以下方式联系我们,我们将尽快给您回复,并为您提供最真诚的服务,谢谢。